TipRanks
Encompass Health (DE:HSOA)
XETRA:HSOA
Germany Market

Encompass Health (HSOA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

HSOA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Encompass
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HSOA Stock 12 Month Forecast

Average Price Target

€130.90
▲(27.09% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is €130.90 with a high forecast of €138.23 and a low forecast of €124.86. The average price target represents a 27.09% change from the last price of €103.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"€77","108":"€108","139":"€139","92.5":"€92.5","123.5":"€123.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":138.23364225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€138.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.90081821666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€130.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.856193,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€124.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,92.5,108,123.5,139],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108,110.32566478846154,112.65132957692308,114.97699436538461,117.30265915384615,119.62832394230769,121.95398873076923,124.27965351923078,126.6053183076923,128.93098309615385,131.25664788461538,133.58231267307693,135.90797746153845,{"y":138.23364225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108,109.76160140128205,111.5232028025641,113.28480420384615,115.0464056051282,116.80800700641025,118.5696084076923,120.33120980897436,122.09281121025641,123.85441261153846,125.61601401282051,127.37761541410256,129.1392168153846,{"y":130.90081821666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108,109.29663023076922,110.59326046153846,111.88989069230769,113.18652092307693,114.48315115384615,115.77978138461539,117.07641161538461,118.37304184615385,119.66967207692308,120.96630230769232,122.26293253846154,123.55956276923078,{"y":124.856193,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.218,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.262,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.269,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.335,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.562,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.496,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.699,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.183,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.674,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.846,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.834,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.817,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€138.23Average Price Target€130.90Lowest Price Target€124.86
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
€138.23
Buy
34.21%
Upside
Reiterated
10/12/26
Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC) and RegenXBio (NASDAQ: RGNX)
TD Cowen
€124.86
Buy
21.22%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC), Shattuck Labs (NASDAQ: STTK) and Arcus Biosciences (NYSE: RCUS)
Raymond James Analyst forecast on DE:HSOA
Raymond James
Raymond James
€133.77
Buy
29.88%
Upside
Reiterated
09/28/26
Analysts Offer Insights on NA Companies: Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) and Encompass Health (NYSE: EHC)
Deutsche Bank  Analyst forecast on DE:HSOA
Deutsche Bank
Deutsche Bank
€126.64
Buy
22.95%
Upside
Reiterated
09/18/26
Analysts Offer Insights on NA Companies: Encompass Health (NYSE: EHC) and Meta Platforms (NASDAQ: META)
KeyBanc
€131.1
Buy
27.28%
Upside
Reiterated
09/17/26
KeyBanc Sticks to Its Buy Rating for Encompass Health (EHC)
Truist Financial Analyst forecast on DE:HSOA
Truist Financial
Truist Financial
€133.77
Buy
29.88%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)
Mizuho Securities Analyst forecast on DE:HSOA
Mizuho Securities
Mizuho Securities
€124.86
Buy
21.22%
Upside
Reiterated
08/11/26
Encompass Health (EHC) Receives a Buy from Mizuho Securities
Bank of America Securities Analyst forecast on DE:HSOA
Bank of America Securities
Bank of America Securities
€133.77→€136.45
Buy
32.48%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)
Barclays
€124.86→€128.42
Buy
24.68%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Encompass Health (EHC)
William Blair Analyst forecast on DE:HSOA
William Blair
William Blair
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
Stephens Analyst forecast on DE:HSOA
Unknown Analyst
Stephens
Not Ranked
Stephens
€124.86
Buy
21.22%
Upside
Reiterated
05/04/26
Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
€138.23
Buy
34.21%
Upside
Reiterated
10/12/26
Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC) and RegenXBio (NASDAQ: RGNX)
TD Cowen
€124.86
Buy
21.22%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Encompass Health (NYSE: EHC), Shattuck Labs (NASDAQ: STTK) and Arcus Biosciences (NYSE: RCUS)
Raymond James Analyst forecast on DE:HSOA
Raymond James
Raymond James
€133.77
Buy
29.88%
Upside
Reiterated
09/28/26
Analysts Offer Insights on NA Companies: Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) and Encompass Health (NYSE: EHC)
Deutsche Bank  Analyst forecast on DE:HSOA
Deutsche Bank
Deutsche Bank
€126.64
Buy
22.95%
Upside
Reiterated
09/18/26
Analysts Offer Insights on NA Companies: Encompass Health (NYSE: EHC) and Meta Platforms (NASDAQ: META)
KeyBanc
€131.1
Buy
27.28%
Upside
Reiterated
09/17/26
KeyBanc Sticks to Its Buy Rating for Encompass Health (EHC)
Truist Financial Analyst forecast on DE:HSOA
Truist Financial
Truist Financial
€133.77
Buy
29.88%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)
Mizuho Securities Analyst forecast on DE:HSOA
Mizuho Securities
Mizuho Securities
€124.86
Buy
21.22%
Upside
Reiterated
08/11/26
Encompass Health (EHC) Receives a Buy from Mizuho Securities
Bank of America Securities Analyst forecast on DE:HSOA
Bank of America Securities
Bank of America Securities
€133.77→€136.45
Buy
32.48%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)
Barclays
€124.86→€128.42
Buy
24.68%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Encompass Health (EHC)
William Blair Analyst forecast on DE:HSOA
William Blair
William Blair
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
Stephens Analyst forecast on DE:HSOA
Unknown Analyst
Stephens
Not Ranked
Stephens
€124.86
Buy
21.22%
Upside
Reiterated
05/04/26
Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
OVIDOvid Therapeutics
OMCLOmnicell
IMUXImmunic
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Encompass Health

3 Months
Ann HynesMizuho Securities
Success Rate
18/27 ratings generated profit
67%
Average Return
+5.15%
Copying Ann Hynes's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.15% per trade.
1 Year
Pito ChickeringDeutsche Bank
Success Rate
10/11 ratings generated profit
91%
Average Return
+20.85%
Copying Pito Chickering's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +20.85% per trade.
2 Years
Pito ChickeringDeutsche Bank
Success Rate
11/11 ratings generated profit
100%
Average Return
+47.75%
Copying Pito Chickering's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HSOA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
0
0
0
0
Buy
16
12
14
14
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
12
14
14
14
In the current month, HSOA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HSOA average Analyst price target in the past 3 months is 130.90.
Each month's total comprises the sum of three months' worth of ratings.

HSOA Financial Forecast

HSOA Earnings Forecast

Next quarter’s earnings estimate for HSOA is €1.21 with a range of €1.11 to €1.25. The previous quarter’s EPS was €1.38. HSOA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.
Next quarter’s earnings estimate for HSOA is €1.21 with a range of €1.11 to €1.25. The previous quarter’s EPS was €1.38. HSOA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.

HSOA Sales Forecast

Next quarter’s sales forecast for HSOA is €1.43B with a range of €1.42B to €1.44B. The previous quarter’s sales results were €1.42B. HSOA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.
Next quarter’s sales forecast for HSOA is €1.43B with a range of €1.42B to €1.44B. The previous quarter’s sales results were €1.42B. HSOA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.

HSOA Stock Forecast FAQ

What is DE:HSOA’s average 12-month price target, according to analysts?
Based on analyst ratings, Encompass Health’s 12-month average price target is 130.90.
    What is DE:HSOA’s upside potential, based on the analysts’ average price target?
    Encompass Health has 27.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Encompass Health a Buy, Sell or Hold?
          Encompass Health has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Encompass Health’s share price target?
            The average share price target for Encompass Health is 130.90. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €138.23 ,and the lowest forecast is €124.86. The average share price target represents 27.09% Increase from the current price of €103.
              What do analysts say about Encompass Health?
              Encompass Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Encompass Health?
                To buy shares of DE:HSOA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.